GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
Source | Last Updated |
---|---|
GlycoNAVI Proteins | September 04, 2024 |
PDB ID | UniProt ID | Title ▲ | Descriptor |
---|---|---|---|
7RYN | P01850 | CD1a-sulfatide-gdTCR complex | |
7RYN | A0A0C4DH28 | CD1a-sulfatide-gdTCR complex | |
7RYN | P01848 | CD1a-sulfatide-gdTCR complex | |
7RYN | A0A1B0GX56 | CD1a-sulfatide-gdTCR complex | |
3OV6 | P61769 | CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide) | Beta-2-microglobulin, T-cell surface glycoprotein CD1c, T-cell surface glycoprotein CD1b |
3OV6 | P29016 | CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide) | Beta-2-microglobulin, T-cell surface glycoprotein CD1c, T-cell surface glycoprotein CD1b |
3OV6 | P29017 | CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide) | Beta-2-microglobulin, T-cell surface glycoprotein CD1c, T-cell surface glycoprotein CD1b |
4ONO | P61769 | CD1c in complex with PM (phosphomycoketide) | T-cell surface glycoprotein CD1c |
4ONO | P29016 | CD1c in complex with PM (phosphomycoketide) | T-cell surface glycoprotein CD1c |
4ONO | P29017 | CD1c in complex with PM (phosphomycoketide) | T-cell surface glycoprotein CD1c |
6C15 | P29017 | CD1c in complex with phosphatidylcholine | |
6C15 | P61769 | CD1c in complex with phosphatidylcholine | |
7MX4 | P29016 | CD1c with antigen analogue 1 | |
7MX4 | P29017 | CD1c with antigen analogue 1 | |
7MX4 | P61769 | CD1c with antigen analogue 1 | |
7MXF | P29016 | CD1c with antigen analogue 2 | |
7MXF | P29017 | CD1c with antigen analogue 2 | |
7MXF | P61769 | CD1c with antigen analogue 2 | |
7MXH | P29016 | CD1c with antigen analogue 3 | |
7MXH | P29017 | CD1c with antigen analogue 3 | |
7MXH | P61769 | CD1c with antigen analogue 3 | |
5VL3 | S6B291 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | 5VL3 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | S6B291 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | 5VL3 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | Q8TCD0 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | Q8TCD0 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
5VL3 | P20273 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | B-cell receptor CD22, Epratuzumab Fab Heavy Chain,Epratuzumab Fab Heavy Chain, Epratuzumab Fab Light Chain,Epratuzumab Fab Light Chain |
7O52 | 7O52 | CD22 d6-d7 in complex with Fab m971 | |
6OPQ | B3UES2 | CD4- and 17-bound HIV-1 Env B41 SOSIP frozen with LMNG | Envelope glycoprotein gp160, 17b Fab light chain, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4, 17b Fab heavy chain |
6OPQ | B3UEZ6 | CD4- and 17-bound HIV-1 Env B41 SOSIP frozen with LMNG | Envelope glycoprotein gp160, 17b Fab light chain, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4, 17b Fab heavy chain |
6OPQ | P01730 | CD4- and 17-bound HIV-1 Env B41 SOSIP frozen with LMNG | Envelope glycoprotein gp160, 17b Fab light chain, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4, 17b Fab heavy chain |
6OPQ | 6OPQ | CD4- and 17-bound HIV-1 Env B41 SOSIP frozen with LMNG | Envelope glycoprotein gp160, 17b Fab light chain, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4, 17b Fab heavy chain |
6OPN | B3UES2 | CD4- and 17-bound HIV-1 Env B41 SOSIP in complex with small molecule GO35 | Envelope glycoprotein gp160, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4 |
6OPN | B3UEZ6 | CD4- and 17-bound HIV-1 Env B41 SOSIP in complex with small molecule GO35 | Envelope glycoprotein gp160, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4 |
6OPN | P01730 | CD4- and 17-bound HIV-1 Env B41 SOSIP in complex with small molecule GO35 | Envelope glycoprotein gp160, Envelope glycoprotein gp41, T-cell surface glycoprotein CD4 |
5IWL | 5IWL | CD47-diabody complex | 5F9 diabody, Leukocyte surface antigen CD47 |
5IWL | Q08722 | CD47-diabody complex | 5F9 diabody, Leukocyte surface antigen CD47 |
6JMR | P08195 | CD98hc extracellular domain bound to HBJ127 Fab and MEM-108 Fab | Antibody, 4F2 cell-surface antigen heavy chain |
6JMR | 6JMR | CD98hc extracellular domain bound to HBJ127 Fab and MEM-108 Fab | Antibody, 4F2 cell-surface antigen heavy chain |
1QJW | P07987 | CEL6A (Y169F) WITH A NON-HYDROLYSABLE CELLOTETRAOSE | CELLOBIOHYDROLASE CEL6A (FORMERLY CALLED CBH II) (E.C.3.2.1.91) |
1HGW | P07987 | CEL6A D175A mutant | |
1HGY | P07987 | CEL6A D221A mutant | |
1QK0 | P07987 | CEL6A WITH A NON-HYDROLYSABLE CELLOTETRAOSE | CELLOBIOHYDROLASE CEL6A (FORMERLY CALLED CBH II) (E.C.3.2.1.91) |
1EGN | P62694 | CELLOBIOHYDROLASE CEL7A (E223S, A224H, L225V, T226A, D262G) MUTANT | |
1Q2B | P62694 | CELLOBIOHYDROLASE CEL7A WITH DISULPHIDE BRIDGE ADDED ACROSS EXO-LOOP BY MUTATIONS D241C AND D249C | |
1Q2E | P00725 | CELLOBIOHYDROLASE CEL7A WITH LOOP DELETION 245-252 AND BOUND NON-HYDROLYSABLE CELLOTETRAOSE | EXOCELLOBIOHYDROLASE I (E.C.3.2.1.91) |
5OA5 | P62694 | CELLOBIOHYDROLASE I (CEL7A) FROM HYPOCREA JECORINA WITH IMPROVED THERMAL STABILITY | |
6GRN | P62694 | CELLOBIOHYDROLASE I (CEL7A) FROM Trichoderma reesei with S-dihydroxypropranolol in the active site | |
1BVW | Q9C1S9 | CELLOBIOHYDROLASE II (CEL6A) FROM HUMICOLA INSOLENS |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024